Tannaz Jamialahmadi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tannaz Jamialahmadi has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Amirhossein Sahebkar
Mashhad University of Medical Sciences
27 shared publications - Habib Yaribeygi
Research Center of Physiology, Semnan University of Medical Sciences, Semnan, Iran
7 shared publications - Mina Maleki
Urology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
6 shared publications - Alexandra E. Butler
Royal College of Surgeons of Ireland, Adliya, Bahrain
5 shared publications - Prashant Kesharwani
Dr. Harisingh Gour Vishwavidyalaya (A Central University)
4 shared publications - Maciej Banach
Department of Preventive Cardiology and Lipidology, Medical University of Lodz (MUL), Poland
3 shared publications
Latest Publications
- Open Access
- 12 February 2026
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 9 (2) , e70166
Impact of Monacolin K‐Containing Supplements on Lipid Profile: A Meta‐Analysis of Randomised Controlled Trials
Background: Natural products have gained attention as alternative strategies for managing dyslipidemia, particularly in individuals who are resistant or unwilling to use conventional pharmacotherapies. Monacolin K, a compound derived from natural sources, has demonstrated potential benefits in improving lipid profile indices across various doses and supplementation durations. This study aimed to quantitatively evaluate the effects of monacolin K‐containing products on plasma lipid levels through a meta‐analysis of clinical trials. Methods: Data were extracted from studies that included placebo or inactive control groups, and the analysis was conducted using Comprehensive Meta‐Analysis (CMA) V4 software. Results: Our findings indicate that monacolin K‐containing supplements are effective in lowering lipid levels, particularly low‐density lipoprotein cholesterol (LDL‐C). Conclusion: These results highlight the potential of monacolin K as a promising adjunct therapy for hypercholesterolemia management, especially for patients who have not achieved LDL‐C targets with standard care or are intolerant to or unwilling to use statin therapy.
- 12 February 2026
- Published by Wiley in Endocrinology, Diabetes & Metabolism
- Vol. 9 (2) , e70166
Open AccessImpact of Monacolin K‐Containing Supplements on Lipid Profile: A Meta‐Analysis of Randomised Controlled Trials
Background: Natural products have gained attention as alternative strategies for managing dyslipidemia, particularly in individuals who are resistant or unwilling to use conventional pharmacotherapies. Monacolin K, a compound derived from natural sources, has demonstrated potential benefits in improving lipid profile indices across various doses and supplementation durations. This study aimed to quantitatively evaluate the effects of monacolin K‐containing products on plasma lipid levels through a meta‐analysis of clinical trials. Methods: Data were extracted from studies that included placebo or inactive control groups, and the analysis was conducted using Comprehensive Meta‐Analysis (CMA) V4 software. Results: Our findings indicate that monacolin K‐containing supplements are effective in lowering lipid levels, particularly low‐density lipoprotein cholesterol (LDL‐C). Conclusion: These results highlight the potential of monacolin K as a promising adjunct therapy for hypercholesterolemia management, especially for patients who have not achieved LDL‐C targets with standard care or are intolerant to or unwilling to use statin therapy.
- 12 February 2026
- Published by SAGE Publications in Bariatric Surgical Practice and Patient Care
- Vol. 21 (1) , 53-62
Changes in the Phase Angle after Bariatric Surgery: A Meta-Analysis
Background: Phase angle (PhA), a parameter derived from bioelectrical impedance analysis, is associated with lean mass and muscle mass. Bariatric surgery can result in significant changes in body composition. The objective of this meta-analysis was to determine the impact of bariatric surgery on PhA. Methods: A systematic review and meta-analysis were conducted following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, including studies up to January 2025 from five databases. Eligible studies assessed PhA alterations before and after bariatric surgery. Results: Thirteen studies with a total of 825 patients were included. Significant PhA reduction was observed following bariatric surgery (weighted mean difference: −0.922; 95% confidence interval [CI]: −1.063, −0.781; p < 0.001). Random-effects meta-regression showed a significant association between ΔPhA and ΔBMI (slope: 0.072; 95% CI: 0.033, 0.112; p = 0.0003) and Δfat-free mass (slope: 0.080; 95% CI: 0.052, 0.107; p < 0.001), but no association with Δfat mass. PhA values decreased significantly with following bariatric surgery, but there were no differences between Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG). Conclusions: This meta-analysis offers evidence regarding the impact of bariatric surgery on bioimpedance parameters, including PhA, in individuals with obesity.
- 12 February 2026
- Published by SAGE Publications in Bariatric Surgical Practice and Patient Care
- Vol. 21 (1) , 53-62
Changes in the Phase Angle after Bariatric Surgery: A Meta-Analysis
Background: Phase angle (PhA), a parameter derived from bioelectrical impedance analysis, is associated with lean mass and muscle mass. Bariatric surgery can result in significant changes in body composition. The objective of this meta-analysis was to determine the impact of bariatric surgery on PhA. Methods: A systematic review and meta-analysis were conducted following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, including studies up to January 2025 from five databases. Eligible studies assessed PhA alterations before and after bariatric surgery. Results: Thirteen studies with a total of 825 patients were included. Significant PhA reduction was observed following bariatric surgery (weighted mean difference: −0.922; 95% confidence interval [CI]: −1.063, −0.781; p < 0.001). Random-effects meta-regression showed a significant association between ΔPhA and ΔBMI (slope: 0.072; 95% CI: 0.033, 0.112; p = 0.0003) and Δfat-free mass (slope: 0.080; 95% CI: 0.052, 0.107; p < 0.001), but no association with Δfat mass. PhA values decreased significantly with following bariatric surgery, but there were no differences between Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy (SG). Conclusions: This meta-analysis offers evidence regarding the impact of bariatric surgery on bioimpedance parameters, including PhA, in individuals with obesity.
- Open Access
- 1 January 2026
- Published by Wiley in Cardiovascular Therapeutics
- Vol. 2026 (1) , 7328020
PCSK9 and Atrial Fibrillation: A New Perspective on an Old Problem
Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a novel contributor to atrial fibrillation (AF) pathophysiology. Recent studies suggest that elevated PCSK9 levels may promote AF through multiple mechanisms, including platelet activation, oxidative stress, vascular calcification, and structural atrial remodeling. PCSK9 inhibitors such as alirocumab, evolocumab, and newer agents like inclisiran have shown potential in reducing AF incidence and cardiovascular events, particularly in high‐risk populations. However, evidence from randomized controlled trials with AF as a primary clinical endpoint is limited. Further mechanistic and interventional research is warranted to establish optimized therapeutic strategies targeting PCSK9 in AF prevention and management.
- 1 January 2026
- Published by Wiley in Cardiovascular Therapeutics
- Vol. 2026 (1) , 7328020
Open AccessPCSK9 and Atrial Fibrillation: A New Perspective on an Old Problem
Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a novel contributor to atrial fibrillation (AF) pathophysiology. Recent studies suggest that elevated PCSK9 levels may promote AF through multiple mechanisms, including platelet activation, oxidative stress, vascular calcification, and structural atrial remodeling. PCSK9 inhibitors such as alirocumab, evolocumab, and newer agents like inclisiran have shown potential in reducing AF incidence and cardiovascular events, particularly in high‐risk populations. However, evidence from randomized controlled trials with AF as a primary clinical endpoint is limited. Further mechanistic and interventional research is warranted to establish optimized therapeutic strategies targeting PCSK9 in AF prevention and management.
- Open Access
- 1 January 2026
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 2026 (1)
Recent Advances in Nanoformulations of GLP‐1 Mimetics for Enhanced Antidiabetic Efficacy and Stability
The application of nanotechnology in pharmaceutical delivery systems has provided innovative approaches to overcome the limitations of conventional antidiabetic therapies. Glucagon‐like peptide‐1 (GLP‐1) mimetics are potent therapeutic agents for type 2 diabetes mellitus; however, their short plasma half‐life, enzymatic degradation, and frequent dosing requirements restrict clinical outcomes. Nanoformulation strategies have shown substantial potential to enhance the pharmacokinetic and pharmacodynamic profiles of GLP‐1 mimetics through controlled release, protection from enzymatic degradation, and targeted delivery. This review provides a comprehensive overview of recent developments in nanoformulated GLP‐1 delivery systems, including lipid‐based carriers, polymeric nanoparticles, micelles, and hydrogel‐based delivery matrices. Emphasis is placed on formulation approaches that improve peptide stability, prolong circulation time, and facilitate site‐specific delivery to pancreatic or hepatic tissues. The discussion also includes key insights into physicochemical optimization, encapsulation efficiency, and stimuli‐responsive release mechanisms. Despite promising preclinical outcomes, translational progress remains limited, highlighting the necessity for in‐depth pharmacokinetic, safety, and scalability studies. Overall, nano‐enabled GLP‐1 delivery platforms represent a promising advancement toward more effective, patient‐friendly, and sustainable diabetes management solutions.
- 1 January 2026
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 2026 (1)
Open AccessRecent Advances in Nanoformulations of GLP‐1 Mimetics for Enhanced Antidiabetic Efficacy and Stability
The application of nanotechnology in pharmaceutical delivery systems has provided innovative approaches to overcome the limitations of conventional antidiabetic therapies. Glucagon‐like peptide‐1 (GLP‐1) mimetics are potent therapeutic agents for type 2 diabetes mellitus; however, their short plasma half‐life, enzymatic degradation, and frequent dosing requirements restrict clinical outcomes. Nanoformulation strategies have shown substantial potential to enhance the pharmacokinetic and pharmacodynamic profiles of GLP‐1 mimetics through controlled release, protection from enzymatic degradation, and targeted delivery. This review provides a comprehensive overview of recent developments in nanoformulated GLP‐1 delivery systems, including lipid‐based carriers, polymeric nanoparticles, micelles, and hydrogel‐based delivery matrices. Emphasis is placed on formulation approaches that improve peptide stability, prolong circulation time, and facilitate site‐specific delivery to pancreatic or hepatic tissues. The discussion also includes key insights into physicochemical optimization, encapsulation efficiency, and stimuli‐responsive release mechanisms. Despite promising preclinical outcomes, translational progress remains limited, highlighting the necessity for in‐depth pharmacokinetic, safety, and scalability studies. Overall, nano‐enabled GLP‐1 delivery platforms represent a promising advancement toward more effective, patient‐friendly, and sustainable diabetes management solutions.
- Open Access
- 30 September 2025
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 26 (9)
Lerodalcibep: Another Crucial Addition to the Dyslipidaemia Arsenal
- 30 September 2025
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 26 (9)
Open AccessLerodalcibep: Another Crucial Addition to the Dyslipidaemia Arsenal
- 17 September 2024
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 398 (2) , 1299-1304
Curcuminoids as natural modulators of necroptosis: therapeutic implications
- 17 September 2024
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 398 (2) , 1299-1304
Curcuminoids as natural modulators of necroptosis: therapeutic implications
- 20 June 2024
- Published by Wiley in Phytotherapy Research
- Vol. 38 (8) , 4081-4098
The role of natural products as PCSK9 modulators: A review
A variety of mechanisms and drugs have been shown to attenuate cardiovascular disease (CVD) onset and/or progression. Recent researchers have identified a potential role of proprotein convertase subtilisin/kexin type 9 (PCSK9) in modulating lipid metabolism and reducing plasma low density lipoprotein (LDL) levels. PCSK9 is the central protein in the metabolism of LDL cholesterol (LDL‐C) owing to its major function in LDL receptor (LDLR) degradation. Due to the close correlation of cardiovascular disease with lipid levels, many in vivo and in vitro investigations are currently underway studying the physiological role of PCSK9. Furthermore, many studies are actively investigating the mechanisms of various compounds that influence lipid associated‐disorders and their associated cardiovascular diseases. PCSK9 inhibitors have been shown to have significant impact in the prevention of emerging cardiovascular diseases. Natural products can effectively be used as PCSK9 inhibitors to control lipid levels through various mechanisms. In this review, we evaluate the role of phytochemicals and natural products in the regulation of PCSK9, and their ability to prevent cardiovascular diseases. Moreover, we describe their mechanisms of action, which have not to date been delineated.
- 20 June 2024
- Published by Wiley in Phytotherapy Research
- Vol. 38 (8) , 4081-4098
The role of natural products as PCSK9 modulators: A review
A variety of mechanisms and drugs have been shown to attenuate cardiovascular disease (CVD) onset and/or progression. Recent researchers have identified a potential role of proprotein convertase subtilisin/kexin type 9 (PCSK9) in modulating lipid metabolism and reducing plasma low density lipoprotein (LDL) levels. PCSK9 is the central protein in the metabolism of LDL cholesterol (LDL‐C) owing to its major function in LDL receptor (LDLR) degradation. Due to the close correlation of cardiovascular disease with lipid levels, many in vivo and in vitro investigations are currently underway studying the physiological role of PCSK9. Furthermore, many studies are actively investigating the mechanisms of various compounds that influence lipid associated‐disorders and their associated cardiovascular diseases. PCSK9 inhibitors have been shown to have significant impact in the prevention of emerging cardiovascular diseases. Natural products can effectively be used as PCSK9 inhibitors to control lipid levels through various mechanisms. In this review, we evaluate the role of phytochemicals and natural products in the regulation of PCSK9, and their ability to prevent cardiovascular diseases. Moreover, we describe their mechanisms of action, which have not to date been delineated.
- 17 July 2023
- Published by Wiley in Phytotherapy Research
- Vol. 37 (10) , 4429-4441
Impact of pomegranate juice on blood pressure: A systematic review and meta‐analysis
Despite the importance of polyphenol‐rich fruits in decreasing cardiovascular mortality, the impact of pomegranate juice (PJ) on blood pressure is still unclear. To determine the effect of PJ on blood pressure. PubMed, Scopus, ISI Web of Science, and Cochrane Library were searched comprehensively using relevant keywords. All studies using pomegranate juice alone were included although limited to human studies and the English language. A random‐effects model and the generic inverse variance approach were used to determine quantitative data synthesis. Meta‐analysis of 14 clinical trials (n = 573 individuals) demonstrated a reduction in systolic BP (SBP) with pomegranate juice (MD: −5.02 mmHg, 95% CI: −7.55 to −2.48, p < 0.001). Effect of study duration showed pomegranate juice intake ≤2 months significantly decreased SBP (MD: −4.59 mmHg, 95% CI: −7.10 to −2.08, p < 0.001) and DBP (MD: −2.94 mmHg, 95% CI: −5.25 to −0.63, p = 0.01). Consumption of ≤300 mL pomegranate juice daily reduced SBP (MD: −6.11 mmHg, 95% CI: −9.22 to −3.00, p < 0.001). Counterintuitively, >300 mL/day of pomegranate juice showed no effect on SBP (MD: −3.28 mmHg, 95% CI: −6.85 to 0.27, p = 0.07) but a significant DBP reduction occurred (MD: −3.10 mmHg, 95% CI: −5.74 to −0.47, p = 0.02). Meta‐regression showed that the SBP‐lowering effect of pomegranate juice was associated with the dose of supplementation (p < 0.001). Pomegranate juice appeared to decrease SBP and DBP in a dose‐dependent manner, but the benefit was lost after 2 months of pomegranate juice intake.
- 17 July 2023
- Published by Wiley in Phytotherapy Research
- Vol. 37 (10) , 4429-4441
Impact of pomegranate juice on blood pressure: A systematic review and meta‐analysis
Despite the importance of polyphenol‐rich fruits in decreasing cardiovascular mortality, the impact of pomegranate juice (PJ) on blood pressure is still unclear. To determine the effect of PJ on blood pressure. PubMed, Scopus, ISI Web of Science, and Cochrane Library were searched comprehensively using relevant keywords. All studies using pomegranate juice alone were included although limited to human studies and the English language. A random‐effects model and the generic inverse variance approach were used to determine quantitative data synthesis. Meta‐analysis of 14 clinical trials (n = 573 individuals) demonstrated a reduction in systolic BP (SBP) with pomegranate juice (MD: −5.02 mmHg, 95% CI: −7.55 to −2.48, p < 0.001). Effect of study duration showed pomegranate juice intake ≤2 months significantly decreased SBP (MD: −4.59 mmHg, 95% CI: −7.10 to −2.08, p < 0.001) and DBP (MD: −2.94 mmHg, 95% CI: −5.25 to −0.63, p = 0.01). Consumption of ≤300 mL pomegranate juice daily reduced SBP (MD: −6.11 mmHg, 95% CI: −9.22 to −3.00, p < 0.001). Counterintuitively, >300 mL/day of pomegranate juice showed no effect on SBP (MD: −3.28 mmHg, 95% CI: −6.85 to 0.27, p = 0.07) but a significant DBP reduction occurred (MD: −3.10 mmHg, 95% CI: −5.74 to −0.47, p = 0.02). Meta‐regression showed that the SBP‐lowering effect of pomegranate juice was associated with the dose of supplementation (p < 0.001). Pomegranate juice appeared to decrease SBP and DBP in a dose‐dependent manner, but the benefit was lost after 2 months of pomegranate juice intake.
- Open Access
- 21 April 2023
- Published by Forschungsgesellschaft für Arbeitsphysiologie und Arbeitsschutz e.V. in EXCLI Journal
- Vol. 22, 403-414
Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders
Diabetic patients are at higher risk of liver dysfunction compared with the normal population. Thus, using hypoglycemic agents to improve liver efficiency is important in these patients. Sodium-glucose cotransporters-2 inhibitors (SGLT2i) are newly developed antidiabetic drugs with potent glucose-lowering effects. However, recent limited evidence suggests that they have extra-glycemic benefits and may be able to exert protective effects on the liver. Hence, these drugs could serve as promising pharmacological agents with multiple benefits against different hepatic disorders. In this review, the current knowledge about the possible effects of SGLT2 inhibitors on different forms of liver complications and possible underlying mechanisms are discussed.
- 21 April 2023
- Published by Forschungsgesellschaft für Arbeitsphysiologie und Arbeitsschutz e.V. in EXCLI Journal
- Vol. 22, 403-414
Open AccessHepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders
Diabetic patients are at higher risk of liver dysfunction compared with the normal population. Thus, using hypoglycemic agents to improve liver efficiency is important in these patients. Sodium-glucose cotransporters-2 inhibitors (SGLT2i) are newly developed antidiabetic drugs with potent glucose-lowering effects. However, recent limited evidence suggests that they have extra-glycemic benefits and may be able to exert protective effects on the liver. Hence, these drugs could serve as promising pharmacological agents with multiple benefits against different hepatic disorders. In this review, the current knowledge about the possible effects of SGLT2 inhibitors on different forms of liver complications and possible underlying mechanisms are discussed.
- 10 April 2023
- Published by Wiley in Cell Biochemistry and Function
- Vol. 41 (4) , 392-398
SGLT2 inhibitors and autophagy in diabetes
Autophagy is a physiological event in mammalian cells to promote cell survival and efficiency in tissues, but it may turn to be a pathological process in disease conditions such as in diabetes. Chronic hyperglycemia induces aberrant autophagy and promotes cellular death as a main underlying cause of diabetes‐related complications. Therefore, autophagy‐modifying therapy may be of value to prevent the development of complications. Sodium‐glucose cotransporter 2 inhibitors (SGLT2is) are a class of newly introduced antidiabetic drugs that achieve normoglycemia through causing overt glycosuria. There is evidence that these drugs may have pleiotropic extra‐glycemic benefits, but their effect on the autophagy process is unclear; therefore, this review was undertaken to clarify the possible effects of SGLT2is on autophagy.
- 10 April 2023
- Published by Wiley in Cell Biochemistry and Function
- Vol. 41 (4) , 392-398
SGLT2 inhibitors and autophagy in diabetes
Autophagy is a physiological event in mammalian cells to promote cell survival and efficiency in tissues, but it may turn to be a pathological process in disease conditions such as in diabetes. Chronic hyperglycemia induces aberrant autophagy and promotes cellular death as a main underlying cause of diabetes‐related complications. Therefore, autophagy‐modifying therapy may be of value to prevent the development of complications. Sodium‐glucose cotransporter 2 inhibitors (SGLT2is) are a class of newly introduced antidiabetic drugs that achieve normoglycemia through causing overt glycosuria. There is evidence that these drugs may have pleiotropic extra‐glycemic benefits, but their effect on the autophagy process is unclear; therefore, this review was undertaken to clarify the possible effects of SGLT2is on autophagy.